Events | 2023.06.17
Sling Therapeutics Presents Data Demonstrating Linsitinib Prevents Thyroid Eye Disease Progression in a Mouse Model at ENDO 2023
- Treatment with linsitinib in a clinically relevant mouse model demonstrated a significant reduction in autoimmune response and classical Thyroid Eye Disease (TED) symptoms, independent of TED severity - - Ongoing global Phase 2b LIDS clinical trial evaluating linsitinib for treatment of...
For more information, please visit
https://www.prnewswire.com/news-releases[...]el-at-endo-2023-301853460.html
